Sugi Predict

Sugi Predict / Compounds / SCHEMBL6769397

SCHEMBL6769397

SCHEMBL6769397

CN(C)C=CC(=O)c1ccccc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.59
▸ MAPT P10636 7/20 0.58
▸ KMT2A Q03164 4/20 0.58
▸ MAPK1 P28482 3/20 0.58
▸ TDP1 Q9NUW8 3/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ NPC1 O15118 1/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ BCHE P06276 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ GUSB P08236 1/20 0.56
▸ MAOB P27338 9/20 0.53
▸ MAOA P21397 5/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ TP53 P04637 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ ALOX12 P18054 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30152192 1.00 RECQL (0.59) RECQLMAPTKMT2AMAPK1TDP1
SCHEMBL29690244 1.00 RECQL (0.59) RECQLMAPTKMT2AMAPK1TDP1
SCHEMBL6769396 1.00 RECQL (0.59) RECQLMAPTKMT2AMAPK1TDP1
SCHEMBL12315710 0.81 RECQL (0.59) RECQLMAPTKMT2ATDP1MEN1
SCHEMBL29750390 0.81 RECQL (0.59) RECQLMAPTKMT2ATDP1MEN1
SCHEMBL3742734 0.81 RECQL (0.59) RECQLMAPTKMT2ATDP1MEN1
SCHEMBL29176318 0.81 RECQL (0.59) RECQLMAPTKMT2ATDP1MEN1
SCHEMBL13978671 0.81 MAPT (0.51) MAPTKMT2AMAPK1TDP1MEN1
SCHEMBL2210433 0.80 TDP1 (0.67) RECQLMAPTMAPK1TDP1NPC1
SCHEMBL7136836 0.80 RECQL (0.58) RECQLMAPTKMT2ATDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1000012-A1 PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 — — EP claimed
WO-1999006351-A1 PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 — — WO claimed
US-12624044-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-05-12 — — US disclosed
CN-112010844-B Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor 中国药科大学 2023-07-25 — — CN disclosed
CN-114539197-B Synthesis method of 3-fluoroalkyl substituted chromone derivative 浙江工业大学 2023-05-30 — — CN disclosed
US-20230115350-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. 2023-04-13 — — US disclosed
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 — — US disclosed
CN-114539197-A Synthetic method of 3-fluoroalkyl substituted chromone derivative 浙江工业大学 2022-05-27 — — CN disclosed
US-20210293825-A1 METHODS FOR PRECISION THERAPEUTIC TARGETING OF HUMAN CANCER CELL MOTILITY AND KITS THEREOF THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2021-09-23 — — US disclosed
WO-2020251971-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 — — WO disclosed
CN-112010844-A Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor 中国药科大学 2020-12-01 — — CN disclosed
WO-2015114102-A1 SILYL SUBSTITUTED AZADIBENZOFURANS AND AZADIBENZOTHIOPHENES BASF SE (DE) 2015-08-06 — — WO disclosed
US-20040242633-A1 Beta3 adrenergic agonists EVERS BRITTA (DE) 2004-12-02 — — US disclosed
US-6730792-B2 PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS ELI LILLY AND COMPANY 2004-05-04 — — US disclosed
US-20030191156-A1 Beta3 adrenergic agonists JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2003-10-09 — — US disclosed
EP-1303509-A1 BETA3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2003-04-23 — — EP disclosed
WO-2002006276-A1 BETA3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2002-01-24 — — WO disclosed
EP-1000012-A1 PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 — — EP disclosed
US-5932745-A HYDROXYLIC SOLVENT AMERICAN HOME PRODUCTS CORPORATION (US) 1999-08-03 — — US disclosed
WO-1999006351-A1 PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230115350-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 RECQL 389/4885MAPT 506/4885KMT2A 3787/4885
US-20030191156-A1 Beta3 adrenergic agonists ADRB3, ADRB1, ADRB2 RECQL 4054/4885MAPT 1813/4885KMT2A 3262/4885
US-20040242633-A1 Beta3 adrenergic agonists ADRB3, ADRB1, ADRB2 RECQL 3997/4885MAPT 2096/4885KMT2A 3460/4885
US-12624044-B2 SMARCA degraders and uses thereof SMARCA1, SMARCC1, SMARCA2 RECQL 882/4885MAPT 2169/4885KMT2A 212/4885
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 RECQL 793/4885MAPT 1445/4885KMT2A 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.